Flubendazole treatment for intestinal worm infections
Raised to date
$4.3M
of $5.3M offered across 1 Form D filing
Zero Point Five Therapeutics, Inc., also known as ZP5 Therapeutics, is a biotechnology company focused on developing effective treatments for neglected tropical diseases, particularly soil-transmitted helminthiasis (STH). The company aims to create accessible therapies for diseases that disproportionately affect marginalized communities worldwide, addressing a critical health crisis caused by intestinal parasitic infections.
ZP5 Therapeutics stands out for its commitment to addressing the unmet medical needs of neglected tropical diseases, particularly focusing on scalable and affordable treatments.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Apr 17, 2025 | Equity | $4.3M/ $5.3M | Form D |
Pharmaceuticals
ZP5-9676 is a drug candidate based on flubendazole and is currently in Phase 3 clinical trials, aimed at treating infections caused by soil-transmitted helminths including hookworm, roundworm, and whipworm.
Built for
Children and low-resource communities affected by STHs
